nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Epirubicin—thyroid cancer	0.304	0.401	CbGbCtD
Tapentadol—UGT1A9—Sorafenib—thyroid cancer	0.282	0.371	CbGbCtD
Tapentadol—CYP2C19—Sorafenib—thyroid cancer	0.0566	0.0746	CbGbCtD
Tapentadol—CYP2C9—Sorafenib—thyroid cancer	0.0471	0.062	CbGbCtD
Tapentadol—CYP2D6—Sorafenib—thyroid cancer	0.0431	0.0567	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—thyroid cancer	0.0261	0.0344	CbGbCtD
Tapentadol—Visual impairment—Vandetanib—thyroid cancer	0.00177	0.00823	CcSEcCtD
Tapentadol—Eye disorder—Vandetanib—thyroid cancer	0.00171	0.00798	CcSEcCtD
Tapentadol—Cardiac disorder—Vandetanib—thyroid cancer	0.0017	0.00792	CcSEcCtD
Tapentadol—Angiopathy—Vandetanib—thyroid cancer	0.00166	0.00774	CcSEcCtD
Tapentadol—Mediastinal disorder—Vandetanib—thyroid cancer	0.00165	0.00769	CcSEcCtD
Tapentadol—Breast disorder—Sorafenib—thyroid cancer	0.00162	0.00752	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00161	0.0075	CcSEcCtD
Tapentadol—Mental disorder—Vandetanib—thyroid cancer	0.00161	0.00748	CcSEcCtD
Tapentadol—Nasopharyngitis—Sorafenib—thyroid cancer	0.0016	0.00744	CcSEcCtD
Tapentadol—Malnutrition—Vandetanib—thyroid cancer	0.0016	0.00743	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00158	0.00734	CcSEcCtD
Tapentadol—Vision blurred—Vandetanib—thyroid cancer	0.0015	0.007	CcSEcCtD
Tapentadol—Tremor—Vandetanib—thyroid cancer	0.00149	0.00696	CcSEcCtD
Tapentadol—Abdominal discomfort—Sorafenib—thyroid cancer	0.00148	0.0069	CcSEcCtD
Tapentadol—Erectile dysfunction—Sorafenib—thyroid cancer	0.00142	0.00663	CcSEcCtD
Tapentadol—Loss of consciousness—Vandetanib—thyroid cancer	0.0014	0.00653	CcSEcCtD
Tapentadol—Weight decreased—Sorafenib—thyroid cancer	0.0014	0.00651	CcSEcCtD
Tapentadol—Cough—Vandetanib—thyroid cancer	0.00139	0.00648	CcSEcCtD
Tapentadol—Convulsion—Vandetanib—thyroid cancer	0.00138	0.00644	CcSEcCtD
Tapentadol—Infestation NOS—Sorafenib—thyroid cancer	0.00138	0.00641	CcSEcCtD
Tapentadol—Infestation—Sorafenib—thyroid cancer	0.00138	0.00641	CcSEcCtD
Tapentadol—Arthralgia—Vandetanib—thyroid cancer	0.00136	0.00633	CcSEcCtD
Tapentadol—Anxiety—Vandetanib—thyroid cancer	0.00135	0.0063	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00135	0.00628	CcSEcCtD
Tapentadol—Dry mouth—Vandetanib—thyroid cancer	0.00133	0.00619	CcSEcCtD
Tapentadol—Oedema—Vandetanib—thyroid cancer	0.0013	0.00606	CcSEcCtD
Tapentadol—Infection—Vandetanib—thyroid cancer	0.00129	0.00602	CcSEcCtD
Tapentadol—Lung disorder—Epirubicin—thyroid cancer	0.00129	0.00599	CcSEcCtD
Tapentadol—Nervous system disorder—Vandetanib—thyroid cancer	0.00128	0.00595	CcSEcCtD
Tapentadol—Skin disorder—Vandetanib—thyroid cancer	0.00126	0.00589	CcSEcCtD
Tapentadol—Urinary tract disorder—Sorafenib—thyroid cancer	0.00122	0.00569	CcSEcCtD
Tapentadol—Connective tissue disorder—Sorafenib—thyroid cancer	0.00122	0.00566	CcSEcCtD
Tapentadol—Urethral disorder—Sorafenib—thyroid cancer	0.00121	0.00564	CcSEcCtD
Tapentadol—Lung disorder—Doxorubicin—thyroid cancer	0.00119	0.00554	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00119	0.00553	CcSEcCtD
Tapentadol—Insomnia—Vandetanib—thyroid cancer	0.00118	0.00549	CcSEcCtD
Tapentadol—Paraesthesia—Vandetanib—thyroid cancer	0.00117	0.00545	CcSEcCtD
Tapentadol—Dyspnoea—Vandetanib—thyroid cancer	0.00116	0.00541	CcSEcCtD
Tapentadol—Feeling hot—Epirubicin—thyroid cancer	0.00116	0.0054	CcSEcCtD
Tapentadol—Cardiac disorder—Sorafenib—thyroid cancer	0.00115	0.00534	CcSEcCtD
Tapentadol—Dyspepsia—Vandetanib—thyroid cancer	0.00115	0.00534	CcSEcCtD
Tapentadol—Decreased appetite—Vandetanib—thyroid cancer	0.00113	0.00527	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00112	0.00524	CcSEcCtD
Tapentadol—Fatigue—Vandetanib—thyroid cancer	0.00112	0.00523	CcSEcCtD
Tapentadol—Angiopathy—Sorafenib—thyroid cancer	0.00112	0.00522	CcSEcCtD
Tapentadol—Immune system disorder—Sorafenib—thyroid cancer	0.00112	0.0052	CcSEcCtD
Tapentadol—Mediastinal disorder—Sorafenib—thyroid cancer	0.00111	0.00519	CcSEcCtD
Tapentadol—Constipation—Vandetanib—thyroid cancer	0.00111	0.00519	CcSEcCtD
Tapentadol—Mental disorder—Sorafenib—thyroid cancer	0.00108	0.00504	CcSEcCtD
Tapentadol—Malnutrition—Sorafenib—thyroid cancer	0.00108	0.00501	CcSEcCtD
Tapentadol—Feeling hot—Doxorubicin—thyroid cancer	0.00107	0.005	CcSEcCtD
Tapentadol—Thinking abnormal—Epirubicin—thyroid cancer	0.000994	0.00463	CcSEcCtD
Tapentadol—Angioedema—Sorafenib—thyroid cancer	0.000984	0.00458	CcSEcCtD
Tapentadol—Syncope—Sorafenib—thyroid cancer	0.000965	0.0045	CcSEcCtD
Tapentadol—Dysarthria—Epirubicin—thyroid cancer	0.000962	0.00448	CcSEcCtD
Tapentadol—Loss of consciousness—Sorafenib—thyroid cancer	0.000946	0.00441	CcSEcCtD
Tapentadol—Cough—Sorafenib—thyroid cancer	0.000939	0.00437	CcSEcCtD
Tapentadol—Asthenia—Vandetanib—thyroid cancer	0.000934	0.00435	CcSEcCtD
Tapentadol—Coordination abnormal—Epirubicin—thyroid cancer	0.000927	0.00432	CcSEcCtD
Tapentadol—Pruritus—Vandetanib—thyroid cancer	0.000921	0.00429	CcSEcCtD
Tapentadol—Thinking abnormal—Doxorubicin—thyroid cancer	0.00092	0.00428	CcSEcCtD
Tapentadol—Arthralgia—Sorafenib—thyroid cancer	0.000916	0.00427	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00091	0.00424	CcSEcCtD
Tapentadol—Abnormal dreams—Epirubicin—thyroid cancer	0.000899	0.00419	CcSEcCtD
Tapentadol—Dry mouth—Sorafenib—thyroid cancer	0.000896	0.00417	CcSEcCtD
Tapentadol—Diarrhoea—Vandetanib—thyroid cancer	0.000891	0.00415	CcSEcCtD
Tapentadol—Dysarthria—Doxorubicin—thyroid cancer	0.00089	0.00415	CcSEcCtD
Tapentadol—Anaphylactic shock—Sorafenib—thyroid cancer	0.000878	0.00409	CcSEcCtD
Tapentadol—Infection—Sorafenib—thyroid cancer	0.000873	0.00406	CcSEcCtD
Tapentadol—Shock—Sorafenib—thyroid cancer	0.000864	0.00402	CcSEcCtD
Tapentadol—Nervous system disorder—Sorafenib—thyroid cancer	0.000862	0.00401	CcSEcCtD
Tapentadol—Dizziness—Vandetanib—thyroid cancer	0.000861	0.00401	CcSEcCtD
Tapentadol—Coordination abnormal—Doxorubicin—thyroid cancer	0.000857	0.00399	CcSEcCtD
Tapentadol—Skin disorder—Sorafenib—thyroid cancer	0.000853	0.00397	CcSEcCtD
Tapentadol—Abnormal dreams—Doxorubicin—thyroid cancer	0.000832	0.00388	CcSEcCtD
Tapentadol—Vomiting—Vandetanib—thyroid cancer	0.000828	0.00386	CcSEcCtD
Tapentadol—Rash—Vandetanib—thyroid cancer	0.000821	0.00382	CcSEcCtD
Tapentadol—Dermatitis—Vandetanib—thyroid cancer	0.00082	0.00382	CcSEcCtD
Tapentadol—Headache—Vandetanib—thyroid cancer	0.000816	0.0038	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.0008	0.00373	CcSEcCtD
Tapentadol—Mental disability—Epirubicin—thyroid cancer	0.00079	0.00368	CcSEcCtD
Tapentadol—Dyspnoea—Sorafenib—thyroid cancer	0.000783	0.00365	CcSEcCtD
Tapentadol—Nausea—Vandetanib—thyroid cancer	0.000774	0.0036	CcSEcCtD
Tapentadol—Dyspepsia—Sorafenib—thyroid cancer	0.000773	0.0036	CcSEcCtD
Tapentadol—Decreased appetite—Sorafenib—thyroid cancer	0.000764	0.00356	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000758	0.00353	CcSEcCtD
Tapentadol—Fatigue—Sorafenib—thyroid cancer	0.000757	0.00353	CcSEcCtD
Tapentadol—Constipation—Sorafenib—thyroid cancer	0.000751	0.0035	CcSEcCtD
Tapentadol—Mental disability—Doxorubicin—thyroid cancer	0.000731	0.0034	CcSEcCtD
Tapentadol—Hot flush—Epirubicin—thyroid cancer	0.000706	0.00329	CcSEcCtD
Tapentadol—Menopausal symptoms—Epirubicin—thyroid cancer	0.0007	0.00326	CcSEcCtD
Tapentadol—Urticaria—Sorafenib—thyroid cancer	0.000698	0.00325	CcSEcCtD
Tapentadol—Lethargy—Epirubicin—thyroid cancer	0.000674	0.00314	CcSEcCtD
Tapentadol—Osteoarthritis—Epirubicin—thyroid cancer	0.000661	0.00308	CcSEcCtD
Tapentadol—Hot flush—Doxorubicin—thyroid cancer	0.000653	0.00304	CcSEcCtD
Tapentadol—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000648	0.00302	CcSEcCtD
Tapentadol—Hypersensitivity—Sorafenib—thyroid cancer	0.000647	0.00301	CcSEcCtD
Tapentadol—Asthenia—Sorafenib—thyroid cancer	0.00063	0.00294	CcSEcCtD
Tapentadol—Lethargy—Doxorubicin—thyroid cancer	0.000624	0.0029	CcSEcCtD
Tapentadol—Pruritus—Sorafenib—thyroid cancer	0.000622	0.00289	CcSEcCtD
Tapentadol—Ataxia—Epirubicin—thyroid cancer	0.000621	0.00289	CcSEcCtD
Tapentadol—Osteoarthritis—Doxorubicin—thyroid cancer	0.000611	0.00285	CcSEcCtD
Tapentadol—Diarrhoea—Sorafenib—thyroid cancer	0.000601	0.0028	CcSEcCtD
Tapentadol—Breast disorder—Epirubicin—thyroid cancer	0.000597	0.00278	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000595	0.00277	CcSEcCtD
Tapentadol—Nasopharyngitis—Epirubicin—thyroid cancer	0.000591	0.00275	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000583	0.00271	CcSEcCtD
Tapentadol—Dizziness—Sorafenib—thyroid cancer	0.000581	0.00271	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—thyroid cancer	0.000575	0.00268	CcSEcCtD
Tapentadol—Vomiting—Sorafenib—thyroid cancer	0.000559	0.0026	CcSEcCtD
Tapentadol—Rash—Sorafenib—thyroid cancer	0.000554	0.00258	CcSEcCtD
Tapentadol—Dermatitis—Sorafenib—thyroid cancer	0.000553	0.00258	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—thyroid cancer	0.000552	0.00257	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00055	0.00256	CcSEcCtD
Tapentadol—Headache—Sorafenib—thyroid cancer	0.00055	0.00256	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000547	0.00255	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000539	0.00251	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000531	0.00247	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—thyroid cancer	0.000527	0.00246	CcSEcCtD
Tapentadol—Nausea—Sorafenib—thyroid cancer	0.000522	0.00243	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—thyroid cancer	0.000517	0.00241	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—thyroid cancer	0.000509	0.00237	CcSEcCtD
Tapentadol—Infestation—Epirubicin—thyroid cancer	0.000509	0.00237	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—thyroid cancer	0.000495	0.0023	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000491	0.00229	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—thyroid cancer	0.000488	0.00227	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—thyroid cancer	0.000478	0.00223	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—thyroid cancer	0.000471	0.00219	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—thyroid cancer	0.000471	0.00219	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—thyroid cancer	0.000465	0.00217	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—thyroid cancer	0.000458	0.00213	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—thyroid cancer	0.000455	0.00212	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—thyroid cancer	0.000451	0.0021	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—thyroid cancer	0.000449	0.00209	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—thyroid cancer	0.000448	0.00209	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—thyroid cancer	0.00044	0.00205	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—thyroid cancer	0.00043	0.002	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—thyroid cancer	0.000427	0.00199	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—thyroid cancer	0.000424	0.00198	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000421	0.00196	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000418	0.00194	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000416	0.00193	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—thyroid cancer	0.000415	0.00193	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—thyroid cancer	0.000414	0.00193	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—thyroid cancer	0.000413	0.00192	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—thyroid cancer	0.000412	0.00192	CcSEcCtD
Tapentadol—Chills—Epirubicin—thyroid cancer	0.00041	0.00191	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—thyroid cancer	0.000407	0.0019	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—thyroid cancer	0.0004	0.00186	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—thyroid cancer	0.000398	0.00185	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—thyroid cancer	0.000395	0.00184	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—thyroid cancer	0.000392	0.00183	CcSEcCtD
Tapentadol—Tension—Epirubicin—thyroid cancer	0.00039	0.00182	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—thyroid cancer	0.000386	0.0018	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—thyroid cancer	0.000384	0.00179	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—thyroid cancer	0.000382	0.00178	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000381	0.00177	CcSEcCtD
Tapentadol—Chills—Doxorubicin—thyroid cancer	0.000379	0.00177	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—thyroid cancer	0.000375	0.00175	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—thyroid cancer	0.00037	0.00173	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—thyroid cancer	0.000368	0.00171	CcSEcCtD
Tapentadol—Agitation—Epirubicin—thyroid cancer	0.000366	0.0017	CcSEcCtD
Tapentadol—Tension—Doxorubicin—thyroid cancer	0.000361	0.00168	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—thyroid cancer	0.000357	0.00166	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—thyroid cancer	0.000357	0.00166	CcSEcCtD
Tapentadol—Syncope—Epirubicin—thyroid cancer	0.000357	0.00166	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—thyroid cancer	0.000352	0.00164	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—thyroid cancer	0.00035	0.00163	CcSEcCtD
Tapentadol—Cough—Epirubicin—thyroid cancer	0.000347	0.00162	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—thyroid cancer	0.000347	0.00162	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—thyroid cancer	0.000345	0.00161	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—thyroid cancer	0.000339	0.00158	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—thyroid cancer	0.000338	0.00158	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—thyroid cancer	0.000338	0.00157	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000336	0.00157	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—thyroid cancer	0.000331	0.00154	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—thyroid cancer	0.000331	0.00154	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—thyroid cancer	0.00033	0.00154	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—thyroid cancer	0.000327	0.00152	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—thyroid cancer	0.000325	0.00151	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—thyroid cancer	0.000325	0.00151	CcSEcCtD
Tapentadol—Oedema—Epirubicin—thyroid cancer	0.000325	0.00151	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—thyroid cancer	0.000324	0.00151	CcSEcCtD
Tapentadol—Infection—Epirubicin—thyroid cancer	0.000323	0.0015	CcSEcCtD
Tapentadol—Cough—Doxorubicin—thyroid cancer	0.000321	0.0015	CcSEcCtD
Tapentadol—Shock—Epirubicin—thyroid cancer	0.000319	0.00149	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—thyroid cancer	0.000319	0.00149	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—thyroid cancer	0.000318	0.00148	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—thyroid cancer	0.000317	0.00148	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—thyroid cancer	0.000315	0.00147	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—thyroid cancer	0.000314	0.00146	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—thyroid cancer	0.000313	0.00146	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—thyroid cancer	0.000312	0.00145	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000311	0.00145	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—thyroid cancer	0.000306	0.00143	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—thyroid cancer	0.000303	0.00141	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—thyroid cancer	0.000303	0.00141	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—thyroid cancer	0.0003	0.0014	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—thyroid cancer	0.0003	0.0014	CcSEcCtD
Tapentadol—Infection—Doxorubicin—thyroid cancer	0.000298	0.00139	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000296	0.00138	CcSEcCtD
Tapentadol—Shock—Doxorubicin—thyroid cancer	0.000296	0.00138	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—thyroid cancer	0.000295	0.00137	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—thyroid cancer	0.000294	0.00137	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—thyroid cancer	0.000293	0.00137	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—thyroid cancer	0.000292	0.00136	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—thyroid cancer	0.000292	0.00136	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00029	0.00135	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—thyroid cancer	0.000289	0.00135	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—thyroid cancer	0.000289	0.00134	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—thyroid cancer	0.000286	0.00133	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—thyroid cancer	0.000282	0.00131	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—thyroid cancer	0.000281	0.00131	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00028	0.00131	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—thyroid cancer	0.00028	0.0013	CcSEcCtD
Tapentadol—Constipation—Epirubicin—thyroid cancer	0.000278	0.00129	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000274	0.00127	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—thyroid cancer	0.000272	0.00127	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—thyroid cancer	0.00027	0.00126	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—thyroid cancer	0.000268	0.00125	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—thyroid cancer	0.000268	0.00125	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—thyroid cancer	0.000267	0.00124	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—thyroid cancer	0.000264	0.00123	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—thyroid cancer	0.000261	0.00122	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000259	0.00121	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—thyroid cancer	0.000259	0.00121	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—thyroid cancer	0.000258	0.0012	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—thyroid cancer	0.000257	0.0012	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—thyroid cancer	0.000248	0.00115	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—thyroid cancer	0.000239	0.00111	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—thyroid cancer	0.000239	0.00111	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—thyroid cancer	0.000233	0.00108	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—thyroid cancer	0.00023	0.00107	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—thyroid cancer	0.000222	0.00103	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—thyroid cancer	0.000221	0.00103	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—thyroid cancer	0.000216	0.001	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—thyroid cancer	0.000215	0.001	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—thyroid cancer	0.000213	0.00099	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—thyroid cancer	0.000206	0.000961	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—thyroid cancer	0.000206	0.000957	CcSEcCtD
Tapentadol—Rash—Epirubicin—thyroid cancer	0.000205	0.000953	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—thyroid cancer	0.000205	0.000952	CcSEcCtD
Tapentadol—Headache—Epirubicin—thyroid cancer	0.000203	0.000947	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—thyroid cancer	0.000199	0.000925	CcSEcCtD
Tapentadol—Nausea—Epirubicin—thyroid cancer	0.000193	0.000898	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—thyroid cancer	0.000191	0.000889	CcSEcCtD
Tapentadol—Rash—Doxorubicin—thyroid cancer	0.000189	0.000882	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—thyroid cancer	0.000189	0.000881	CcSEcCtD
Tapentadol—Headache—Doxorubicin—thyroid cancer	0.000188	0.000876	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—thyroid cancer	0.000178	0.000831	CcSEcCtD
Tapentadol—UGT2B7—Biological oxidations—RXRA—thyroid cancer	0.000154	0.00586	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—NRG1—thyroid cancer	0.000152	0.00578	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CALCB—thyroid cancer	0.000151	0.00575	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—NRG1—thyroid cancer	0.000149	0.00569	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000149	0.00567	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000149	0.00567	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—RXRA—thyroid cancer	0.000149	0.00566	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	0.000143	0.00543	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000142	0.00543	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—CP—thyroid cancer	0.000141	0.00537	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000141	0.00537	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—SST—thyroid cancer	0.00014	0.00532	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—SST—thyroid cancer	0.000139	0.00531	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000139	0.00528	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CALCB—thyroid cancer	0.000137	0.00523	CbGpPWpGaD
Tapentadol—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000136	0.0052	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000133	0.00506	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CALCB—thyroid cancer	0.000132	0.00505	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—NRG1—thyroid cancer	0.000128	0.00489	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000126	0.00481	CbGpPWpGaD
Tapentadol—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000126	0.00478	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—RXRA—thyroid cancer	0.000125	0.00476	CbGpPWpGaD
Tapentadol—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000124	0.00474	CbGpPWpGaD
Tapentadol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000124	0.00472	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—TSHR—thyroid cancer	0.000124	0.00471	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	0.000123	0.0047	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000122	0.00463	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000121	0.00459	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00012	0.00459	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CALCB—thyroid cancer	0.00012	0.00458	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—SST—thyroid cancer	0.000118	0.00449	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—MINPP1—thyroid cancer	0.000113	0.00431	CbGpPWpGaD
Tapentadol—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	0.000113	0.0043	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CALCB—thyroid cancer	0.000112	0.00426	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000111	0.00424	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000111	0.00422	CbGpPWpGaD
Tapentadol—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000111	0.00422	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.00011	0.00421	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—TSHR—thyroid cancer	0.000109	0.00413	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000105	0.00402	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—PTCH1—thyroid cancer	0.000105	0.00401	CbGpPWpGaD
Tapentadol—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000102	0.00388	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CALCB—thyroid cancer	0.000102	0.00387	CbGpPWpGaD
Tapentadol—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000101	0.00384	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—SST—thyroid cancer	9.62e-05	0.00367	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NDUFA13—thyroid cancer	9.61e-05	0.00366	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	9.37e-05	0.00357	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CALCA—thyroid cancer	9.26e-05	0.00353	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—PTCH1—thyroid cancer	9.23e-05	0.00352	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—MINPP1—thyroid cancer	9.19e-05	0.0035	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—TSHR—thyroid cancer	9.17e-05	0.00349	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CHST14—thyroid cancer	9.04e-05	0.00344	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.86e-05	0.00338	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—PPARG—thyroid cancer	8.44e-05	0.00322	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—SST—thyroid cancer	8.44e-05	0.00321	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CALCA—thyroid cancer	8.12e-05	0.00309	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CALCB—thyroid cancer	8.1e-05	0.00309	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	7.84e-05	0.00299	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NDUFA13—thyroid cancer	7.81e-05	0.00298	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—PTCH1—thyroid cancer	7.8e-05	0.00297	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TRIM33—thyroid cancer	7.68e-05	0.00293	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	7.61e-05	0.0029	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—TPR—thyroid cancer	7.56e-05	0.00288	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CP—thyroid cancer	7.56e-05	0.00288	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.44e-05	0.00283	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CHST14—thyroid cancer	7.34e-05	0.0028	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—HPGD—thyroid cancer	7.28e-05	0.00278	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	7.15e-05	0.00272	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—SST—thyroid cancer	7.13e-05	0.00272	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CALCB—thyroid cancer	7.11e-05	0.00271	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—TSHR—thyroid cancer	6.99e-05	0.00266	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—AKT1—thyroid cancer	6.9e-05	0.00263	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CALCA—thyroid cancer	6.86e-05	0.00262	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TRIM33—thyroid cancer	6.74e-05	0.00257	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—TSHR—thyroid cancer	6.35e-05	0.00242	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	6.25e-05	0.00238	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PRKAR1A—thyroid cancer	6.25e-05	0.00238	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—TSHR—thyroid cancer	6.13e-05	0.00234	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CALCB—thyroid cancer	6.01e-05	0.00229	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—HPGD—thyroid cancer	5.92e-05	0.00226	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—RXRA—thyroid cancer	5.88e-05	0.00224	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—HRAS—thyroid cancer	5.8e-05	0.00221	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—PTEN—thyroid cancer	5.79e-05	0.00221	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.7e-05	0.00217	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TRIM33—thyroid cancer	5.69e-05	0.00217	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.66e-05	0.00216	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—TSHR—thyroid cancer	5.57e-05	0.00212	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PRKAR1A—thyroid cancer	5.48e-05	0.00209	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—SST—thyroid cancer	5.44e-05	0.00207	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—RXRA—thyroid cancer	5.41e-05	0.00206	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PTCH1—thyroid cancer	5.4e-05	0.00206	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—RXRA—thyroid cancer	5.36e-05	0.00204	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CALCA—thyroid cancer	5.23e-05	0.00199	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—TSHR—thyroid cancer	5.18e-05	0.00197	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TCF7L1—thyroid cancer	5.13e-05	0.00195	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—AKT1—thyroid cancer	5.12e-05	0.00195	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—SST—thyroid cancer	4.94e-05	0.00188	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.8e-05	0.00183	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—SST—thyroid cancer	4.77e-05	0.00182	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.76e-05	0.00181	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CALCA—thyroid cancer	4.75e-05	0.00181	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PTCH1—thyroid cancer	4.73e-05	0.0018	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—TSHR—thyroid cancer	4.71e-05	0.00179	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PRKAR1A—thyroid cancer	4.63e-05	0.00176	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CALCA—thyroid cancer	4.59e-05	0.00175	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TCF7L1—thyroid cancer	4.49e-05	0.00171	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—SST—thyroid cancer	4.33e-05	0.00165	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MINPP1—thyroid cancer	4.32e-05	0.00164	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CDK1—thyroid cancer	4.3e-05	0.00164	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TPR—thyroid cancer	4.18e-05	0.00159	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CALCA—thyroid cancer	4.17e-05	0.00159	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	4.12e-05	0.00157	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—SST—thyroid cancer	4.03e-05	0.00154	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PTCH1—thyroid cancer	4e-05	0.00152	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MINPP1—thyroid cancer	3.97e-05	0.00151	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—thyroid cancer	3.95e-05	0.00151	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MINPP1—thyroid cancer	3.94e-05	0.0015	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CALCA—thyroid cancer	3.88e-05	0.00148	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TCF7L1—thyroid cancer	3.8e-05	0.00145	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CDK1—thyroid cancer	3.77e-05	0.00144	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TSHR—thyroid cancer	3.75e-05	0.00143	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PRKAR1A—thyroid cancer	3.69e-05	0.00141	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NDUFA13—thyroid cancer	3.67e-05	0.0014	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—SST—thyroid cancer	3.66e-05	0.00139	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MEN1—thyroid cancer	3.53e-05	0.00134	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CALCA—thyroid cancer	3.52e-05	0.00134	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CHST14—thyroid cancer	3.45e-05	0.00132	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TPR—thyroid cancer	3.4e-05	0.0013	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NDUFA13—thyroid cancer	3.38e-05	0.00129	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NDUFA13—thyroid cancer	3.35e-05	0.00128	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	3.34e-05	0.00127	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TSHR—thyroid cancer	3.29e-05	0.00125	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PRKAR1A—thyroid cancer	3.24e-05	0.00123	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTCH1—thyroid cancer	3.19e-05	0.00122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CDK1—thyroid cancer	3.19e-05	0.00121	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CHST14—thyroid cancer	3.17e-05	0.00121	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CHST14—thyroid cancer	3.15e-05	0.0012	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—SLC5A5—thyroid cancer	3.13e-05	0.00119	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MEN1—thyroid cancer	3.09e-05	0.00118	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.03e-05	0.00116	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SST—thyroid cancer	2.92e-05	0.00111	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CALCA—thyroid cancer	2.81e-05	0.00107	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTCH1—thyroid cancer	2.8e-05	0.00107	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HPGD—thyroid cancer	2.78e-05	0.00106	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSHR—thyroid cancer	2.78e-05	0.00106	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PRKAR1A—thyroid cancer	2.74e-05	0.00104	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—RXRA—thyroid cancer	2.63e-05	0.001	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MEN1—thyroid cancer	2.61e-05	0.000996	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HPGD—thyroid cancer	2.56e-05	0.000975	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SST—thyroid cancer	2.56e-05	0.000975	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SLC5A5—thyroid cancer	2.55e-05	0.00097	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDK1—thyroid cancer	2.54e-05	0.000968	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HPGD—thyroid cancer	2.54e-05	0.000967	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CALCA—thyroid cancer	2.46e-05	0.000938	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.38e-05	0.000909	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTCH1—thyroid cancer	2.36e-05	0.000901	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.26e-05	0.00086	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDK1—thyroid cancer	2.23e-05	0.000849	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SST—thyroid cancer	2.16e-05	0.000824	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—RXRA—thyroid cancer	2.14e-05	0.000815	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CALCA—thyroid cancer	2.08e-05	0.000793	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.08e-05	0.000792	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.06e-05	0.000784	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRG1—thyroid cancer	2.04e-05	0.000777	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDK1—thyroid cancer	1.88e-05	0.000718	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TERT—thyroid cancer	1.83e-05	0.000698	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRG1—thyroid cancer	1.79e-05	0.000682	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HIF1A—thyroid cancer	1.75e-05	0.000668	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PPARG—thyroid cancer	1.66e-05	0.000633	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TERT—thyroid cancer	1.61e-05	0.000612	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TPR—thyroid cancer	1.6e-05	0.000609	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	1.57e-05	0.000599	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—NRAS—thyroid cancer	1.54e-05	0.000588	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HIF1A—thyroid cancer	1.54e-05	0.000585	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRG1—thyroid cancer	1.51e-05	0.000576	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TPR—thyroid cancer	1.47e-05	0.00056	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TPR—thyroid cancer	1.46e-05	0.000555	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—BRAF—thyroid cancer	1.45e-05	0.000553	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.45e-05	0.000551	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.43e-05	0.000546	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.42e-05	0.000543	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TERT—thyroid cancer	1.36e-05	0.000517	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NRAS—thyroid cancer	1.35e-05	0.000516	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—thyroid cancer	1.35e-05	0.000514	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—thyroid cancer	1.33e-05	0.000506	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.31e-05	0.000498	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.3e-05	0.000495	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIF1A—thyroid cancer	1.3e-05	0.000495	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—thyroid cancer	1.27e-05	0.000485	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.2e-05	0.000456	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—thyroid cancer	1.16e-05	0.000444	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NRAS—thyroid cancer	1.14e-05	0.000436	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—thyroid cancer	1.14e-05	0.000434	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—thyroid cancer	1.13e-05	0.00043	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.12e-05	0.000427	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.1e-05	0.000419	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—thyroid cancer	1.1e-05	0.000418	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.09e-05	0.000416	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—thyroid cancer	1.08e-05	0.00041	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.06e-05	0.000405	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—thyroid cancer	1.06e-05	0.000403	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.02e-05	0.000389	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—thyroid cancer	1.02e-05	0.000389	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—RXRA—thyroid cancer	1.01e-05	0.000383	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—thyroid cancer	9.97e-06	0.00038	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—thyroid cancer	9.9e-06	0.000377	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—thyroid cancer	9.85e-06	0.000375	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.78e-06	0.000372	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—thyroid cancer	9.63e-06	0.000367	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—thyroid cancer	9.28e-06	0.000354	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—thyroid cancer	9.26e-06	0.000353	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—RXRA—thyroid cancer	9.24e-06	0.000352	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—RXRA—thyroid cancer	9.16e-06	0.000349	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRAS—thyroid cancer	9.12e-06	0.000347	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—thyroid cancer	8.96e-06	0.000341	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.91e-06	0.00034	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—thyroid cancer	8.74e-06	0.000333	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—thyroid cancer	8.37e-06	0.000319	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—thyroid cancer	8.14e-06	0.00031	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRAS—thyroid cancer	8e-06	0.000305	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—thyroid cancer	7.85e-06	0.000299	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—thyroid cancer	7.85e-06	0.000299	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—thyroid cancer	7.57e-06	0.000289	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—thyroid cancer	7.39e-06	0.000282	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—thyroid cancer	6.97e-06	0.000266	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—thyroid cancer	6.88e-06	0.000262	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRAS—thyroid cancer	6.76e-06	0.000257	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—thyroid cancer	6.67e-06	0.000254	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—thyroid cancer	6.57e-06	0.00025	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—thyroid cancer	6.35e-06	0.000242	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—thyroid cancer	6.12e-06	0.000233	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—thyroid cancer	5.89e-06	0.000224	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—thyroid cancer	5.85e-06	0.000223	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—thyroid cancer	5.84e-06	0.000222	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—thyroid cancer	5.82e-06	0.000222	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—thyroid cancer	5.79e-06	0.00022	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—thyroid cancer	5.34e-06	0.000203	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—thyroid cancer	5.17e-06	0.000197	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—thyroid cancer	5.16e-06	0.000197	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—thyroid cancer	4.99e-06	0.00019	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—thyroid cancer	4.94e-06	0.000188	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—thyroid cancer	4.59e-06	0.000175	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—thyroid cancer	4.55e-06	0.000173	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—thyroid cancer	4.36e-06	0.000166	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—thyroid cancer	4.35e-06	0.000166	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—thyroid cancer	4e-06	0.000153	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—thyroid cancer	3.97e-06	0.000151	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—thyroid cancer	2.51e-06	9.56e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—thyroid cancer	2.31e-06	8.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—thyroid cancer	2.29e-06	8.72e-05	CbGpPWpGaD
